EAGLE HEALTH INVESTMENTS LP
Q2 2025 Form 13-F

GREENWICH, CONNECTICUT
CIK 0001842545 · CRD 309210 · SEC-registered investment adviser
$405.2M Reported Value Total

EAGLE HEALTH INVESTMENTS LP reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $711,903,596, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
1 fund · $605.3M gross asset value
Hedge Fund: $605.3M
Source: Form ADV filed 2026-03-28
Reported value
$405.2M
Quarter over quarter
+8.6%
Holdings
21
Top-10 concentration
74.3%

Key People

Form ADV owners & control persons
Gary Johnathan Stern
FOUNDER AND CHIEF INVESTMENT OFFICER
Michelle Nmn Dea
CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q2 2025 13F record

Q2 2025 13F filing summary

Q2 2025 Form 13F portfolio summary
Period of report June 30, 2025
Filed August 12, 2025
Form 13F-HR
Reported value $405.2M
Positions 21
Change in reported value +5.2%
New positions 4
Exited positions 3
Position turnover 29.2%
Top-10 concentration 74.3%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q2 2026 13F
Filed Aug 10, 2026
27 $603.3M
Q1 2026 13F
Filed May 15, 2026
26 $571.8M
Q4 2025 13F
Filed Feb 6, 2026
30 $455.1M
Q3 2025 13F
Filed Nov 7, 2025
23 $380.9M
Q2 2025 13F
Filed Aug 12, 2025
21 $405.2M
Q1 2025 13F
Filed May 12, 2025
20 $385.1M
Q4 2024 13F
Filed Feb 12, 2025
18 $407.9M
Q3 2024 13F
Filed Nov 12, 2024
24 $528.0M
Q2 2024 13F
Filed Aug 13, 2024
25 $570.2M
Q1 2024 13F
Filed May 14, 2024
26 $538.2M
Q4 2023 13F
Filed Feb 12, 2024
22 $492.1M
Q3 2023 13F
Filed Oct 27, 2023
23 $453.8M
Q2 2023 13F
Filed Aug 14, 2023
27 $534.8M
Q1 2023 13F
Filed May 12, 2023
27 $513.7M
Q4 2022 13F
Filed Feb 13, 2023
27 $433.5M
Q3 2022 13F
Filed Nov 14, 2022
28 $435.7M
Q2 2022 13F
Filed Aug 11, 2022
28 $428.9M
Q1 2022 13F
Filed May 12, 2022
28 $405.9M
Q4 2021 13F
Filed Feb 10, 2022
28 $410.4M
Q3 2021 13F
Filed Oct 20, 2021
27 $315.3M

3 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q2 2025

Largest Q2 2025 13F positions by reported value
# Holding Reported value % of portfolio
1 INSM INSMED INC $43.1M 10.65%
2 ARGX ARGENX SE $42.7M 10.53%
3 NTRA NATERA INC $39.9M 9.84%
4 ILMN ILLUMINA INC $32.8M 8.09%
5 ICLR ICON PLC $29.5M 7.28%
6 NBIX NEUROCRINE BIOSCIENCES INC $27.3M 6.74%
7 DXCM DEXCOM INC $23.9M 5.9%
8 RARE ULTRAGENYX PHARMACEUTICAL IN $22.8M 5.63%
9 BMRN BIOMARIN PHARMACEUTICAL INC $20.2M 4.98%
10 UNH UNITEDHEALTH GROUP INC $19.0M 4.69%
11 PRCT PROCEPT BIOROBOTICS CORP $17.2M 4.25%
12 ALNY ALNYLAM PHARMACEUTICALS INC $15.0M 3.71%
13 AKRO AKERO THERAPEUTICS INC $12.1M 2.98%
14 EXAS EXACT SCIENCES CORP $11.9M 2.93%
15 BBIO BRIDGEBIO PHARMA INC $11.2M 2.76%
16 GH GUARDANT HEALTH INC $11.0M 2.72%
17 AGIO AGIOS PHARMACEUTICALS INC $11.0M 2.72%
18 SRRK SCHOLAR ROCK HLDG CORP $9.5M 2.36%
19 ISRG INTUITIVE SURGICAL INC $2.4M 0.59%
20 IMCR IMMUNOCORE HLDGS PLC $1.5M 0.36%

Values as reported on the Q2 2025 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings